A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Blood

Volumn 123, Issue 10, 2014, Pages 1447-1454

  Pennell, Dudley J ^a   Porter, John B ^b   Piga, Antonio ^c   Lai, Yongrong ^d   El Beshlawy, Amal ^e   Belhoul, Khawla M ^f   Elalfy, Mohsen ^g   Yesilipek, Akif ^h   Kilinç, Yurdanur ⁱ   Lawniczek, Tomasz ^j   Habr, Dany ^j   Weisskopf, Marianne ^j   Zhang, Yiyun ^j   Aydinok, Yesim ^k  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TURIN   (Italy)

^d GUANGXI MEDICAL UNIVERSITY   (China)

^e Cairo University   (Egypt)

^f Al Wasl Hospital   (United Arab Emirates)

^g Ain Shams University   (Egypt)

^h AKDENIZ UNIVERSITY   (Turkey)

ⁱ CUKUROVA UNIVERSITY   (Turkey)

^j NOVARTIS PHARMA AG   (Switzerland)

^k EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; IRON;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL INFECTION; HEART ARRHYTHMIA; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON INTAKE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENINGITIS; MULTICENTER STUDY; MYOCARDIAL SIDEROSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIDEROSIS; THALASSEMIA MAJOR; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; FEMALE; FERRITINS; HEART; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MEDICATION ADHERENCE; MYOCARDIUM; TREATMENT OUTCOME; TRIAZOLES; TROPONIN T; YOUNG ADULT;

EID: 84897504545     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-497842     Document Type: Article

References (37)

1. Carpenter J-P, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519-1528.
2. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179. (Pubitemid 33139463)
3. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-2978.
4. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica. 2008;93(6):917-920. (Pubitemid 351821730)
5. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
6. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr. 1991;118(4 Pt 1):540-545.
7. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573. (Pubitemid 24265698)
8. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-578. (Pubitemid 24265699)
9. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
10. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-355. (Pubitemid 39468951)
11. Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD Jr, Coates TD, Wood JC. MRI detects myocardial iron in the human heart. Magn Reson Med. 2006;56(3):681-686. (Pubitemid 44338890)
12. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ; Thalassemia International Federation Heart T2* Investigators. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006;91(10):1388-1391. (Pubitemid 44569814)
13. Pepe A, Positano V, Santarelli MF, et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging. 2006;23(5):662-668.
14. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
15. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
16. Westwood MA, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003;18(5):616-620. (Pubitemid 37345172)
17. Westwood MA, Firmin DN, Gildo M, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging. 2005;21(5):531-538. (Pubitemid 41435154)
18. Kirk P, He T, Anderson LJ, et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32(2):315-319.
19. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112(4):535-543. (Pubitemid 41060794)
20. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842-848.
21. Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006;76(3):183-192.
22. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884. (Pubitemid 46598901)
23. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-543.
24. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
25. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28(2):196-208. (Pubitemid 34743754)
26. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48-54.
27. Wood JC, Glynos T, Thompson A, et al. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol. 2010;85(10):818-819.
28. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364-2371.
29. Thalassaemia International Federation. Guidelines for the Clinical Management of Thalassaemia, 2nd Revised Edition. 2008. http://www.thalassaemia. org.cy/wp-content/uploads/pdf/educational-programmes/Publications/ Guidelines%20(2008)/Thalassaemia%20Guidelines%20ENGLISH.pdf.
30. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861. (Pubitemid 40070775)
31. Porter JB, Shah FT. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am. 2010;24(6):1109-1130.
32. EMA Committee for proprietary medical products. Points to consider on switching between superiority and non-inferiorty. 2000. http://www.emea.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003658.pdf. Accessed January 10, 2014.
33. ICH harmonised tripartite guideline. Statistical principles for clinical trials. 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E9/Step4/E9-Guideline.pdf. Accessed January 10, 2014.
34. Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007;25(6):1147-1151. (Pubitemid 46870271)
35. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
36. Cassinerio E, Roghi A, Pedrotti P, et al. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Ann Hematol. 2012;91(9):1443-1449.
37. Pennell DJ, Carpenter J-P, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011;13(1):45.